202 Shares in Amgen Inc. (NASDAQ:AMGN) Acquired by Sierra Ocean LLC

Sierra Ocean LLC acquired a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 202 shares of the medical research company’s stock, valued at approximately $53,000.

Several other large investors have also recently modified their holdings of AMGN. AMF Tjanstepension AB grew its position in Amgen by 16.9% during the 3rd quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after purchasing an additional 17,387 shares during the last quarter. Swedbank AB grew its position in Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock worth $173,639,000 after purchasing an additional 5,751 shares during the last quarter. Inspire Advisors LLC purchased a new stake in Amgen during the 3rd quarter worth approximately $204,000. Blue Trust Inc. grew its position in Amgen by 46.3% during the 3rd quarter. Blue Trust Inc. now owns 3,682 shares of the medical research company’s stock worth $1,150,000 after purchasing an additional 1,166 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC boosted its holdings in shares of Amgen by 8.4% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 2,087 shares of the medical research company’s stock valued at $673,000 after acquiring an additional 162 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, EVP Jonathan P. Graham sold 25,045 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the completion of the transaction, the executive vice president now owns 28,987 shares in the company, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Murdo Gordon sold 8,771 shares of the business’s stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the transaction, the executive vice president now owns 44,186 shares of the company’s stock, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 35,405 shares of company stock worth $10,410,596. Corporate insiders own 0.69% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Leerink Partners dropped their price objective on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Jefferies Financial Group reissued a “buy” rating and set a $380.00 price target on shares of Amgen in a report on Tuesday, November 12th. UBS Group lowered their price target on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Finally, Truist Financial lowered their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a report on Wednesday, January 8th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $314.09.

Amgen Price Performance

Shares of AMGN opened at $291.16 on Tuesday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market cap of $156.51 billion, a PE ratio of 38.56, a P/E/G ratio of 3.01 and a beta of 0.56. The firm has a 50-day simple moving average of $274.12 and a two-hundred day simple moving average of $301.42. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. As a group, analysts forecast that Amgen Inc. will post 20.59 EPS for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.27%. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s payout ratio is 119.21%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.